Evommune, Inc. (NYSE:EVMN) Given Consensus Rating of “Buy” by Brokerages

Evommune, Inc. (NYSE:EVMN) has received an average rating of “Buy” from the fourteen analysts that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, nine have issued a buy recommendation and three have issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $49.25.

A number of brokerages have commented on EVMN. Stifel Nicolaus began coverage on Evommune in a report on Friday, May 1st. They issued a “buy” rating and a $54.00 price objective on the stock. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $48.00 price objective on shares of Evommune in a report on Friday, April 10th. Oppenheimer began coverage on Evommune in a report on Tuesday, April 7th. They issued an “outperform” rating and a $50.00 price objective on the stock. Clear Str raised Evommune to a “strong-buy” rating in a report on Tuesday, March 17th. Finally, Wall Street Zen lowered Evommune from a “hold” rating to a “sell” rating in a report on Saturday, June 13th.

Evommune Trading Up 3.0%

EVMN stock opened at $21.27 on Friday. The firm has a market capitalization of $766.22 million and a PE ratio of -2.24. Evommune has a 1-year low of $13.89 and a 1-year high of $33.20. The business’s 50 day simple moving average is $23.40 and its 200 day simple moving average is $22.23.

Evommune (NYSE:EVMN) last posted its earnings results on Thursday, May 7th. The company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.19. As a group, sell-side analysts predict that Evommune will post -2.85 EPS for the current fiscal year.

Insider Transactions at Evommune

In other Evommune news, insider Gregory S. Moss sold 14,223 shares of the company’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $22.83, for a total value of $324,711.09. Following the transaction, the insider directly owned 60,835 shares of the company’s stock, valued at $1,388,863.05. This represents a 18.95% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director David E. Cohen sold 6,056 shares of the company’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $20.33, for a total value of $123,118.48. Following the completion of the transaction, the director directly owned 17,609 shares in the company, valued at approximately $357,990.97. This represents a 25.59% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 71,928 shares of company stock worth $1,624,145.

Institutional Trading of Evommune

Several large investors have recently modified their holdings of EVMN. EQT Fund Management S.a r.l. acquired a new stake in shares of Evommune during the 4th quarter worth $84,395,000. RA Capital Management L.P. acquired a new stake in shares of Evommune during the 4th quarter worth $59,214,000. Pivotal bioVenture Partners Investment Advisor LLC bought a new stake in Evommune during the fourth quarter worth about $32,989,000. Nan Fung Group Holdings Ltd bought a new stake in Evommune during the fourth quarter worth about $24,670,000. Finally, JPMorgan Chase & Co. acquired a new stake in Evommune during the fourth quarter worth about $22,408,000.

About Evommune

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.